Synergistic cytotoxicity between a protein kinase C inhibitor, UCN-01, and monoclonal antibody to the epidermal growth factor receptor on MDA-468 cells.
Cytotoxic effect of the monoclonal antibody to the epidermal growth factor receptor (anti-EGFR MAb) given alone or in combination with UCN-01, a selective protein kinase C inhibitor, was investigated in vitro. MDA-468 human breast cancer cells expressing both a large amount of EGF receptors and its ligand, transforming growth factor a, were used. A given number of the cells were plated and treated with the MAb and/or UCN-01 for 48 h. These cells were replated and incubated for colony formation assay. Cytotoxicity of the anti-EGFR MAb alone was hardly detected. However, when cells were treated with both anti-EGFR MAb and UCN-01, the combined cytotoxic effect was synergistic.
Tsuchida
E
E
Department of Radiation Medicine, University of Kentucky Medical Center, USA.
Tsuchida
M
M
Urano
M
M
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D006801:Humans; D051379:Mice; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D019311:Staurosporine / Q000031:analogs & derivatives; D014407:Tumor Cells, Cultured
D000470:Alkaloids; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C054852:7-hydroxystaurosporine; D066246:ErbB Receptors; D011493:Protein Kinase C; D019311:Staurosporine